A retrospective safety study on screening of the samples in the clinical biobank of Beijing Hospital.
10.3760/cma.j.cn112150-20210608-00557
- Author:
HeXin LI
1
;
XiaoKun TANG
1
;
SiYuan XU
1
;
XuanMei LUO
2
;
GaoYuan SUN
1
;
HongTao XU
3
;
PengJun ZHANG
4
;
Fei XIAO
1
Author Information
1. Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
2. Beijing Hospital, National Center of Gerontology, the MOH Key Laboratory of Geriatrics, Beijing 100730, China.
3. Department of Clinical Laboratory, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
4. Department of Scientific Research Administration, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Biological Specimen Banks;
COVID-19;
Cross-Sectional Studies;
Hospitals;
Humans;
Retrospective Studies;
SARS-CoV-2
- From:
Chinese Journal of Preventive Medicine
2021;55(9):1149-1152
- CountryChina
- Language:Chinese
-
Abstract:
To investigate whether the laboratory specimens preserved in Beijing Hospital Biobank during a specific period had been contaminated by SARS-Cov-2 through a cross-sectional study, and to establish a retrospective biobank safety screening system. Laboratory specimens were collected from the Department of Respiratory and Critical Care Medicine and the Fever Clinic of Beijing Hospital from November 1, 2019 to January 22, 2020, nucleic acid and serological antibody testing were performed for SARS-CoV-2 in these specimens (including 79 serum, 20 urine, 42 feces and 21 bronchoalveolar lavage fluid specimens). The safety of the stored samples during this period was defined by negative and positive results. Both the nucleic acid test and serological antibody test showed negative for SARS-CoV-2, indicating that these specimens were safely stored in the biobank. High-risk specimens collected in our hospital during the early stage of the COVID-19 outbreak are free of SARS-CoV-2, and a safety screening strategy for the clinical biobank is established to ensure the biosafety of these samples.
